Obamacare enrollees are likely to pay more for their HIV drugs compared to those using private insurance, according to a new analysis.
The analysis released Wednesday from the research firm Avalere Health found that only 16 percent of Obamacare's silver plans this year cover all top HIV drug regimens and charge less than $100 per month per regimen.
Almost half of the silver plans include all 10 of the most commonly used HIV regimens, but many plans charge higher out-of-pocket costs for them, Avalere said.
The finding means that enrollees in the silver plan, the second tier of three plans offered on the exchanges, have to pay more out of pocket. That is critical because patients facing high costs tend to forego taking their medication over time, Avalere said.